A 16 Yin Yang gene expression ratio signature for ER+/node− breast cancer

Breast cancer is one of the leading causes of cancer death in women. It is a complex and heterogeneous disease with different clinical outcomes. Stratifying patients into subgroups with different outcomes could help guide clinical decision making. In this study, we used two opposing groups of genes, Yin and Yang, to develop a prognostic expression ratio signature. Using the METABRIC cohort we identified a16‐gene signature capable of stratifying breast cancer patients into four risk levels with intention that low‐risk patients would not undergo adjuvant systemic therapy, intermediate‐low‐risk patients will be treated with hormonal therapy only, and intermediate‐high‐ and high‐risk groups will be treated by chemotherapy in addition to the hormonal therapy. The 16‐gene signature for four risk level stratifications of breast cancer patients has been validated using 14 independent datasets. Notably, the low‐risk group (n = 51) of 205 estrogen receptor‐positive and node negative (ER+/node−) patients from three different datasets who had not had any systemic adjuvant therapy had 100% 15‐year disease‐specific survival rate. The Concordance Index of YMR for ER+/node negative patients is close to the commercially available signatures. However, YMR showed more significance (HR = 3.7, p = 8.7e‐12) in stratifying ER+/node− subgroup than OncotypeDx (HR = 2.7, p = 1.3e‐7), MammaPrint (HR = 2.5, p = 5.8e‐7), rorS (HR = 2.4, p = 1.4e‐6), and NPI (HR = 2.6, p = 1.2e‐6). YMR signature may be developed as a clinical tool to select a subgroup of low‐risk ER+/node− patients who do not require any adjuvant hormonal therapy (AHT).

[1]  Joe Wright,et al.  Journal clubs--science as conversation. , 2004, The New England journal of medicine.

[2]  R. Eils,et al.  Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2. , 2015, Cancer discovery.

[3]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[4]  I. Mills,et al.  Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1 , 2011, The EMBO journal.

[5]  B. Rasmussen,et al.  Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark. , 2011, Journal of the National Cancer Institute.

[6]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Leigh Murphy,et al.  A 10‐Gene Yin Yang Expression Ratio Signature for Stage IA and IB Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  Ying Yuan,et al.  Identification of Common Prognostic Gene Expression Signatures with Biological Meanings from Microarray Gene Expression Datasets , 2012, PloS one.

[9]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[10]  Aedín C. Culhane,et al.  survcomp: an R/Bioconductor package for performance assessment and comparison of survival models , 2011, Bioinform..

[11]  David M. Thomas,et al.  Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ. , 2009, Cancer research.

[12]  Jack Cuzick,et al.  Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[14]  N. Pearce,et al.  Healthy lifestyle and risk of breast cancer for indigenous and non-indigenous women in New Zealand: a case control study , 2014, BMC Cancer.

[15]  C. Heizmann,et al.  S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. , 2004, Biochemical and biophysical research communications.

[16]  A. Fusco,et al.  CBX7 is a tumor suppressor in mice and humans. , 2012, The Journal of clinical investigation.

[17]  M. Erlander,et al.  HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease , 2013, Breast Cancer Research.

[18]  Balraj Mittal,et al.  Role of GSTM3 Polymorphism in the Risk of Developing Esophageal Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[19]  Cory C. Funk,et al.  The estrogen-regulated transcription factor PITX1 coordinates gene-specific regulation by estrogen receptor-alpha in breast cancer cells. , 2011, Molecular endocrinology.

[20]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[21]  R. Baxter,et al.  IGF binding proteins in cancer: mechanistic and clinical insights , 2014, Nature Reviews Cancer.

[22]  A. Schmidt,et al.  S100P Stimulates Cell Proliferation and Survival via Receptor for Activated Glycation End Products (RAGE)* , 2004, Journal of Biological Chemistry.

[23]  S. Koscielny.  Why Most Gene Expression Signatures of Tumors Have Not Been Useful in the Clinic , 2010, Science Translational Medicine.

[24]  Takeshi Imamura,et al.  TGF‐β receptor‐mediated signalling through Smad2, Smad3 and Smad4 , 1997 .

[25]  F. Couch,et al.  A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen , 2006, Clinical Cancer Research.

[26]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[27]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[28]  J. Bryant,et al.  Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials , 2004, The Lancet.

[29]  Joel S. Parker,et al.  Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer , 2016, Bioinform..

[30]  L. Hood,et al.  Isolation and characterization of human and mouse WDR19,a novel WD-repeat protein exhibiting androgen-regulated expression in prostate epithelium. , 2003, Genomics.

[31]  L. Pusztai,et al.  Multigene prognostic tests in breast cancer: past, present, future , 2015, Breast Cancer Research.

[32]  H. Zhang,et al.  PES1 promotes breast cancer by differentially regulating ERα and ERβ. , 2012, The Journal of clinical investigation.

[33]  T. Eberlein.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[34]  C. Augustine,et al.  Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. , 2013, The Journal of clinical investigation.

[35]  Eytan Domany,et al.  Outcome signature genes in breast cancer: is there a unique set? , 2004, Breast Cancer Research.

[36]  David Venet,et al.  Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome , 2011, PLoS Comput. Biol..

[37]  D. Yee,et al.  Yin Yang Gene Expression Ratio Signature for Lung Cancer Prognosis , 2013, PloS one.

[38]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[39]  Mark T. W. Ebbert,et al.  A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[40]  V. Stojanoff,et al.  Small-molecule modulators of methyl-lysine binding for the CBX7 chromodomain. , 2015, Chemistry & biology.

[41]  Life beyond the walls , 2002, Nature.

[42]  I. Barone,et al.  Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines , 2014, Breast Cancer Research.

[43]  T. Sørlie,et al.  Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status , 2014, BMC Cancer.

[44]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[45]  J. Hopper,et al.  Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. , 2006, Cancer research.

[46]  S. Rocha,et al.  PITX1, a specificity determinant in the HIF-1α-mediated transcriptional response to hypoxia , 2014, Cell cycle.